lisocabtagene maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie,janssen
['cll 004', 'transcend cll 004', 'transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'cll']
time for transcend cll 004 #17icml a step in the right direction for car t in cll but still uncertainty regarding the next step given low response rates for the sd umrd group, perhaps it is the challenge of getting the car t into the right compartment 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem